A Study Of Digital Dermatologic Management For Amivantamab-Associated Skin

Overview

About this study

The purpose of this study is to evaluate the feasibility of a digital health system–enabled dermatologic management platform for patients receiving amivantamab-based therapy, including patient adherence to scheduled image uploads, timeliness of clinician feedback, and the impact on early detection and management of dermatologic adverse events.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults between the ages of 18 and 99

  • Treated at Mayo Clinic Rochester and Florida campuses

  • Either will be starting Amivantamab within 2 weeks of signing consent, or have started Amivantamab in the last 4 months, from date of consent.

Exclusion Criteria:

  • Under the Age of 18

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 06/22/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Contact us for the latest status

Rochester, Minn.

Mayo Clinic principal investigator

Contact us for the latest status

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions